Helio Genomics CEO to Join Terasaki Institute Leadership Board for Biomedical Innovation

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for early cancer detection, Chief Executive Officer Justin Chen Li, has been selected to join the Leadership Board of the Terasaki Institute for Biomedical Innovation at UCLA.
 
“I am deeply honored to have been selected to serve on the board of this prestigious institute here in Southern California that is making dramatic advances in the biomedical sciences with implications worldwide,” said Li. “Its an incredible opportunity to contribute to these groundbreaking efforts, share our expertise, and interact with others who are pursuing similar goals in improving healthcare and saving lives.”
 
The Leadership Board is an advisory group to support the Institute and its mission to invent and foster practical solutions that restore or enhance the health of individuals. It is a volunteer panel of leaders in philanthropy, business, and the clinic who help formulate and execute the institute’s ambitious innovation strategy. Initiations are limited and selective and reflect the recipient’s lifetime achievements.
 
With the inauguration of a new 57,530-sq.-ft. core labs, the Terasaki Institute operates one of the largest independent biomedical innovation infrastructures in Southern California. This infrastructure enables the creation of important and promising scientific platforms with the potential to bring solutions to critical problems in human and planetary health by translating such solutions into lifesaving products and services.
 
“Our institute is engaged in an ambitious strategy to drive breakthrough research into translation across some of the biggest unmet needs in medicine, including cancer,” said Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute. “We are grateful to Justin Li for joining our leadership board and helping to support our translational research mission with his expertise as an entrepreneur and an investor with a long history of accomplishment in biomedical innovation.”
 
Helio Genomics aims to transform the paradigm of cancer screening by developing multi-analyte blood tests with greater sensitivity, specificity, and ease of use compared to current screening modalities using AI technology.
 
The company employs a multi-modal, multi-omics approach to biomarker discovery, utilizing various biological data to understand the mechanisms behind cancer development and progression. Its focus is on translating these insights into user-friendly tools to aid medical decision-making and potentially prevent cancer progression.